MDCO Share Price

Open 38.15 Change Price %
High 38.73 1 Day 0.45 1.18
Low 37.89 1 Week 1.51 4.07
Close 38.60 1 Month -1.40 -3.50
Volume 884227 1 Year 5.34 16.06
52 Week High 55.95
52 Week Low 30.80
MDCO Important Levels
Resistance 2 39.38
Resistance 1 39.06
Pivot 38.41
Support 1 38.14
Support 2 37.82
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

The Medicines Company (NASDAQ: MDCO)

MDCO Technical Analysis 4
As on 23rd Jun 2017 MDCO Share Price closed @ 38.60 and we RECOMMEND Sell for LONG-TERM with Stoploss of 41.18 & Strong Sell for SHORT-TERM with Stoploss of 44.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDCO Target for June
1st Target up-side 46.39
2nd Target up-side 51.02
3rd Target up-side 55.66
1st Target down-side 33.15
2nd Target down-side 28.52
3rd Target down-side 23.88
MDCO Other Details
Segment EQ
Market Capital 1165638144.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
MDCO Address
MDCO
N/A
MDCO Latest News
Interactive Technical Analysis Chart The Medicines Company ( MDCO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on The Medicines Company
MDCO Business Profile
The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.